|
A 63-year-old female with newly diagnosed glioblastoma (gbm) started optune gio therapy on (b)(6), 2026.On august 21, 2026, novocure received a medical record dated august 17, 2026, indicating that the patient experienced scalp irritation and itching and was prescribed hydroxyzine.The medication was also recommended to use for nighttime anxiety related to potential progression of underlying disease.On (b)(6), 2026, the prescribing physician confirmed that the patient experienced skin irritation related to optune gio arrays.The patient was treated with hydroxyzine, which resolved the event, and continued optune gio therapy.According to the physician, the patient was not taking any medications that could have been considered a risk factor for skin irritation.
|